Theravance Biopharma, Inc.
TBPH
$17.05
-$0.01-0.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 104.31M | 109.78M | 107.46M | 80.33M | 77.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 104.31M | 109.78M | 107.46M | 80.33M | 77.21M |
| Cost of Revenue | 26.01M | 31.79M | 37.41M | 39.51M | 40.66M |
| Gross Profit | 78.30M | 77.98M | 70.05M | 40.82M | 36.54M |
| SG&A Expenses | 68.75M | 73.00M | 73.65M | 73.63M | 72.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 94.76M | 104.79M | 111.07M | 113.14M | 112.84M |
| Operating Income | 9.55M | 4.98M | -3.60M | -32.81M | -35.63M |
| Income Before Tax | 58.92M | 136.92M | 129.25M | 47.24M | 40.08M |
| Income Tax Expenses | 5.11M | 22.37M | 23.35M | 17.90M | 27.05M |
| Earnings from Continuing Operations | 53.81 | 114.54 | 105.90 | 29.34 | 13.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 53.81M | 114.54M | 105.90M | 29.34M | 13.03M |
| EBIT | 9.55M | 4.98M | -3.60M | -32.81M | -35.63M |
| EBITDA | 11.10M | 6.58M | -1.98M | -31.17M | -33.96M |
| EPS Basic | 1.06 | 2.27 | 2.09 | 0.58 | 0.25 |
| Normalized Basic EPS | -0.65 | 0.20 | 0.06 | 0.59 | 0.51 |
| EPS Diluted | 1.01 | 2.21 | 2.03 | 0.56 | 0.23 |
| Normalized Diluted EPS | -0.62 | 0.22 | 0.08 | 0.58 | 0.50 |
| Average Basic Shares Outstanding | 204.33M | 202.84M | 201.27M | 199.71M | 198.23M |
| Average Diluted Shares Outstanding | 207.91M | 206.97M | 205.39M | 201.65M | 198.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |